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Preoperative cardiac risk stratification has taken on 
an important role in inpatient medicine.  But per-
haps of even greater importance is the subject of 
perioperative medical management.  Given the 
mounting evidence that preoperative revasculari-
zation is largely ineffective for improving postop-
erative survival over medical management, pe-
rioperative medical therapy to reduce surgical mor-
bidity and mortality has gained importance.  The evidence in favor of perioperative 
beta-blockers has recently come into question but the literature looking at the benefit 
of HMG-CoA reductase inhibitors (statins) appears quite promising. 
Perioperative statins have been studied extensively in the setting of cardiac surgery.  
A recent meta-analysis of multiple RCTs by Hindler et al (4) showed a perioperative 
mortality benefit of 39% for statins in cardiac surgery patients.  The same meta-
analysis showed a 59% relative risk reduction in favor of statins after high-risk vascu-
lar surgery.  However, data on statins in intermediate-risk, noncardiac surgery is 
sparse, with only one large retrospective database survey available to evaluate the 
benefits of statins in this cohort of patients. 
The data supporting the benefit of statins in noncardiac surgery includes one small 
randomized trial and several retrospective studies.  In 2004, Durazzo et al (1) random-
ized 100 patients to either atorvastatin 20 mg qd or placebo, starting at least 30 days 
prior to elective major vascular surgery.  Primary outcome measures included mortal-
ity and cardiovascular events; at 6 months, 8% of the atorvastatin group vs. 26% of the 
placebo group had met an endpoint (p=0.03).  Similarly, a large retrospective chart 
review by Lindenhauer et al (3) demonstrated a significant reduction in mortality be-
tween patients on statins at the time of surgery versus those not on statins.  In 2007, Le 
Manach et al (2) studied the question of what happens when statins are discontinued 
perioperatively; in their retrospective review of almost 700 patients who had under-
gone AAA repair, the occurrence of myonecrosis was assessed with troponin I levels.   
Patients who received continuous statin therapy had a 5-fold lower incidence of (cont) 
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(cont) elevated troponins than did those patients whose statin therapy was discontinued for at least four days 
postoperatively. 
In conclusion, the data thus far strongly suggests that perioperative statin therapy is beneficial in patients un-
dergoing noncardiac surgery.  Unfortunately, due to a lack of randomized trials, the evidence is far from de-
finitive; nevertheless, the early evidence is compelling and may already be able to guide therapy in two areas.  
First, discontinuing statins perioperatively likely increases the rate of adverse cardiac events; second, starting 
statins at least four weeks prior to noncardiac surgery seems to provide cardiovascular benefit for patients 
who are at increased cardiac risk.  More robust data is expected in the near future and, hopefully, will give 
hospitalists another management resource for their perioperative toolkit. 
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CASE OF THE MONTH      Kyle Moylan MD 
Orthopedic Surgery requested an inpatient Internal Medicine consultation for evaluation of an 81 year old 
woman with multiple vertebral fractures of possible pathologic origin.  The patient had been in excellent 
health with no chronic medical problems and took no medications.  Three months prior to admission, she pre-
sented to an outside ER with the acute onset of midline thoracic back pain that started immediately after lifting 
a gallon of milk.  The pain was severe but she had no associated neurologic symptoms.  A plain radiograph 
revealed a vertebral compression fracture (level not specified); no labs were obtained and she was sent home 
with analgesics and a referral to orthopedic clinic in one month.  At that visit, she was prescribed Tylenol and 
offered vertebroplasty but the patient declined.  She presented to the University Hospital ER one month later 
with worsening pain, uncontrolled by the Tylenol; a plain radiograph revealed severe T-6 and L-4 vertebral 
compression fractures; these were not present on films obtained one month prior.  A T-11 anterior wedge de-
formity, presumably the original fracture, was unchanged.  The patient was seen by Orthopedic Surgery in the 
ER; she was prescribed cyclobenzaprine, ibuprofen and a Jewett brace and was set up for an outpatient MRI 
and an orthopedic spine surgery appointment.  There was some discussion of an inpatient evaluation but the 
patient had declined.  With this management, the mid thoracic pain improved but she experienced worsening 
pain in the upper lumbar and thoracolumbar area.          (continued on page 3) 
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